Compare FEIM & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FEIM | BOLD |
|---|---|---|
| Founded | 1961 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.3M | 25.7M |
| IPO Year | 1994 | 2024 |
| Metric | FEIM | BOLD |
|---|---|---|
| Price | $53.51 | $1.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $42.50 | $4.00 |
| AVG Volume (30 Days) | ★ 122.1K | 65.9K |
| Earning Date | 03-17-2026 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | 32.47 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $69,811,000.00 | N/A |
| Revenue This Year | $5.52 | N/A |
| Revenue Next Year | $17.07 | N/A |
| P/E Ratio | $207.36 | ★ N/A |
| Revenue Growth | ★ 26.30 | N/A |
| 52 Week Low | $13.69 | $0.96 |
| 52 Week High | $61.47 | $1.79 |
| Indicator | FEIM | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 46.52 |
| Support Level | $51.37 | $1.10 |
| Resistance Level | $59.91 | $1.20 |
| Average True Range (ATR) | 3.99 | 0.03 |
| MACD | 0.44 | 0.00 |
| Stochastic Oscillator | 67.10 | 25.00 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.